Gilmer recommends accumulating Harvest OneGlobe and Mail reports in its Tuesday edition that Haywood Securities analyst Neal Gilmer recommends accumulating Harvest One Cannabis at its current level. The Globe's David Leeder writes in the Eye On Equities column that on May 30, the Vancouver-based company posted revenue of $3-million for the quarter, down 19 per cent from the second quarter and missing Mr. Gilmer's $4.8-million projection. As result of its weaker-than-anticipated third quarter results, Mr. Gilmer lowered his share target to $1.25 from $1.30, while maintaining his "buy" call. Analysts on average target the shares at $1.63. Mr. Gilmer says in a note: "The Company reported declining sales quarter-over-quarter, primarily driven by a drop off in its consumer segment and a lack of sales from Satipharm. Revenues from United Greeneries were marginally lower than last quarter as the Company shipped product for extraction, reducing the overall supply of available product. Harvest One reported a disappointing quarter of revenue growth and looks to build off this base with a rebound in the current quarter, its fiscal Q4. We are revising our estimates lower based on the results in Q3/19 and a more conservative approach for subsequent quarters."